Medical
-
Satsuma Pharmaceuticals announced that it has initiated the Phase 3 EMERGE trial of STS101 dihydroergotamine (DHE) nasal powder for the acute treatment of migraine. In April 2019, Satsuma announced that it had raised $62 million… Read more . . .
-
Verona Pharma has announced that a Phase 2 trial of its RPL554 ensifentrine DPI for the treatment of COPD met all primary and secondary endpoints related to improvement in lung function. The company had previously… Read more . . .
-
AZ Therapies has announced that the Phase 3 COGNITE study of ALZT-OP1 inhaled cromolyn/oral ibuprofen for the treatment of early stage Alzheimer’s disease has completed enrollment. The company, which announced the initiation of the study… Read more . . .
-
Auris Medical has announced the initiation of the Phase 2 TRAVERS trial of its AM-125 intranasal betahistine for the treatment of acute vertigo resulting from removal of a vestibular schwannoma. Auris is also developing intranasal… Read more . . .
-
Oyster Point Pharma has announced the initiation of the Phase 3 ONSET-2 study of its OC-01 nicotine acetylcholine receptor (nAChR) agonist nasal spray for the treatment of dry eye disease. In October 2018, the company… Read more . . .
-
DPI developer Iconovo has announced that a PK study of its ICOres reservoir-based inhaler demonstrated that the device delivered a budesonide/formoterol dry powder formulation as expected compared to Symbicort Turbuhaler. According to the company, the… Read more . . .
-
Pulmatrix has announced the initiation of a Phase 2 clinical trial of Pulmazole inhaled itraconazole (PUR1900) for the treatment of allergic bronchopulmonary aspergillosis (ABPA) in patients with asthma, with top line data expected in mid 2020.… Read more . . .
-
Inhaled drug developer Savara has announced that the Phase 3 IMPALA study of Molgradex inhaled formulation recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF) for the treatment of autoimmune pulmonary alveolar proteinosis (aPAP) failed to meet its primary… Read more . . .
-
During the 2019 annual meeting of the American Diabetes Association (ADA), Dance Biopharm presented data from the Phase 2 Samba 04 clinical trial of Dance 501 inhaled insulin for the treatment of Type 2 diabetes… Read more . . .
-
Windtree Therapeutics and Eleison Pharmaceuticals have announced results from a study that demonstrated the feasibility of delivering Eleison’s inhaled lipid cisplatin (ILC) via Windtree’s Aerosol Delivery System (ADS). In March 2018, the companies announced that… Read more . . .

Upcoming Events
Sponsored by Intertek
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
December 9-December 11: DDL 2026, Edinburgh, Scotland
April 27-30: RDD Europe 2027, Antibes, France
May 12-13: USP Joint Workshop: Quality and Product Performance Testing of Orally Inhaled and Nasal Drug Products, Rockville, MD, USA
May 30-June 2: ISAM Congress 2027, Dublin, Ireland
June 23: SMI London, London, UK


